Back To Search Results


Editor: Mohit Gupta Updated: 8/28/2023 9:54:24 PM


Penicillins had been very effective against S. aureus; in the past, however, Staphylococcus aureus has become capable of exhibiting resistance against them by producing a penicillin hydrolyzing enzyme – penicillinase. After that, ampicillin was developed to overcome this issue and extend the antimicrobial coverage of penicillins. It is also resistant to acid so it can be administered orally.[1]

Ampicillin has effective minimum inhibitory concentration for most of medically important organisms in infectious disease like Escherichia coli: MIC = 4 mg/L, Staphylococcus aureus: MIC = 0.6-1 mg/L, Streptococcus pneumoniae: MIC = 0.03-0.06 mg/L, Hemophilus influenzae: MIC = 0.25 mg/L.[1] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.

FDA-approved Indications

  • Respiratory tract infection: caused by: Streptococcus pneumoniae, penicillinase, and non-penicillinase-producing Staphylococcus aureus, group A beta-hemolytic Streptococci, Hemophilus influenzae.
  • Bacterial meningitis: caused by Gram-negative bacteria: Neisseria meningitisEscherichia coli, Gram-positive bacteria: Listeria monocytogenes, Group B Streptococci. Adding aminoglycosides increases its effectiveness against gram-negative bacteria.[2]
  • Septicemia and endocarditis: caused by Gram-positive bacteria, including penicillin-susceptible Staphylococcus speciesStreptococcus species, and Enterococcus species. Gram-negative bacteria include Escherichia coliSalmonella species, and Proteus mirabilis. Endocarditis caused by enterococci usually responds to intravenous ampicillin. Adding aminoglycosides with ampicillin may increase its effectiveness when treating endocarditis caused by streptococci.[3]
  • Genitourinary infections: caused by sensitive strains of Escherichia coli and Proteus mirabilis. The CDC no longer recommends ampicillin as a first-line agent in treating gonorrhea.[4]
  • Gastrointestinal infections: caused by Salmonella typhiShigella species, and other Salmonella species, and usually improve with oral or intravenous therapy. Culture must be obtained for susceptibility and antimicrobial sensitivity; however, the clinician may start empiric treatment before receiving the results.[5] 

Off-label Clinical Uses

  • Neonatal group B Streptococcal infection prophylaxis: Administered as an alternative to intramuscular penicillin.[6]
  • Prophylaxis in surgeryAmpicillin is a routinely selected agent in orthopedic surgeries, especially prosthetic implants and dental surgeries.[7]
  • Chorioamnionitis: Ampicillin, in combination with gentamicin, is used to treat chorioamnionitis.[8]
  • Carbapenem-resistant Acinetobacter baumannii (CRAB): According to IDSA 2022 guidelines, ampicillin/sulbactam is the preferred agent for the infection caused by carbapenem-resistant Acinetobacter baumannii(CRAB).[9]

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Ampicillin is a beta-lactam antibiotic and is classified as aminopenicillins.

  • The mode of action of beta-lactam antimicrobials on sensitive organisms can be considered a two-step process: In the first step, the drug binds to primary receptors called membrane-bound penicillin-binding proteins (PBPs). These proteins perform vital roles in cell cycle-related; formation of cell wall peptidoglycan structure. Therefore, the inactivation of PBPs by bound antimicrobials immediately affects their function.
  • The second stage comprises the physiological effects caused by this receptor-ligand interaction. PBPs are involved in the cell wall's late stages of peptidoglycan synthesis. Because peptidoglycan maintains the integrity of the cell wall, which resides in a hypotonic environment, its disruption causes lysis and cell death.[10]
  • It is important to recognize that ampicillin is primarily bactericidal against susceptible bacteria due to its inhibition of cell wall synthesis.
  • Mechanism of resistance: Penicillinase (a β-lactamase) cleaves the beta-lactam ring and results in resistance to ampicillin. Hence ampicillin is usually combined with β-lactamase inhibitors like sulbactam.[11]


Absorption: Ampicillin injection diffuses readily in body tissues and fluids. 

Distribution:  Ampicillin shows low plasma protein binding(20%)) compared to 60 to 90% for other penicillins. Enhanced penetration through the blood-brain barrier and adequate CSF concentration is achieved due to inflammation in meningitis.[12]

Metabolism: Ampicillin is excreted largely unchanged in the urine, and its excretion can be delayed by concurrent administration of probenecid. 

Excretion: The half-life of ampicillin is 0.7 to 1.5 hours in adults with normal kidney function. According to a recent study, the pharmacokinetics of ampicillin vary significantly in late preterm and term neonates; clinicians should be cautious when administering ampicillin to preterm neonates.[13]


Ampicillin administration can be oral, intramuscular, or intravenous. Parenteral administration is preferable for severe or moderately severe infections. The oral route should not be the initial therapy in life-threatening conditions but can follow after parenteral therapy.

Oral Administration

  • When administered orally, it should be on an empty stomach with 1 or 2 full glasses of water to increase absorption.

Intravenous Administration

  • For intravenous administration, ampicillin may be administered as an IV bolus. Reconstitution of vials containing 125, 250, or 500 mg of the drug with 5 ml sterile water is recommended.
  • Vials containing 1 or 2 g should be reconstituted at 7.4 or 14.8 ml of bacteriostatic or sterile water.

Intramuscular Administration

  • If administering ampicillin intramuscularly, the injection should be into a large muscle mass. Reconstitute with bacteriostatic or sterile water to create solutions containing 125 or 250 mg/ml.

Rate of Administration

  • Formulations reconstituted from 125, 250, or 500 mg vials must be given over 3 to 5 minutes by intravenous injection.
  • Formulations reconstituted from 1 or 2 g vials must be given over 10 to 15 minutes by intravenous injection.

GI Tract Infection

  • Bodyweight less than 40 kg: IV/IM 50 mg/kg/day every 6 to 8 hours
  • Bodyweight more than 40 kg: IV/IM 500 mg every 6 hours

GU Tract Infection

  • Bodyweight less than 40 kg: IV/IM 50 mg/kg/day every 6 to 8 hours
  • Bodyweight more than 40 kg: IV/IM 500 mg every 6 hours

Respiratory Tract Infection

  • Bodyweight less than 40 kg: IV/IM 250 to 500 mg/kg/day every 6 to 8 hours
  • Bodyweight more than 40 kg: IV/IM 25 to 50 mg/kg/day every 6 hours

Urinary Tract infection 

  • Caused by ampicillin susceptible enterococcus
  • IV/IM 1 to 2 g every 4 to 6 hrs

Bacterial Meningitis/Septicemia

  • IV 150 to 200 mg/kg/day every every 6 to 8 hours

Listeria Species

  • IV 2 g every 4 hours[14]

Endocarditis Prophylaxis (off-label)

  • In the respiratory tract, oral or dental procedure: IM, IV: 50 mg/kg as a single dose 30 to 60 minutes before the procedure.
  • In gastrointestinal or genitourinary procedure: Only for patients at risk for endocarditis: IV/IM 2g 30 minutes before the procedure, followed by 1 g, 6 hours later with an aminoglycoside.

Endocarditis (off-label)

  • Endocarditis caused by Listeria species
  • IV/IM 200 mg/kg/day every 6 hours for 4 to 6 weeks 

Gonorrhea (not CDC recommended)

  • IV 3.5 g administered once with 1 g probenecid

Streptococcus agalactiae (off-label)

  • Maternal prophylaxis to prevent newborn infection
  • IV first dose 2 g followed by 1 g every 4 hours till delivery[6]

Use in Specific Patient Populations

Patients with Hepatic Impairment: No dose adjustment has been provided in the manufacturer's labeling.

Patients with Renal Impairment: The dosing frequency should be adjusted based on patient CrCl.

  • CrCl <10 mL/min: Administer every 12 to 24 hours
  • CrCl 10-50 mL/min: Administer every 6 to 12 hours 
  • CrCl >50 mL/min: Administer every 6 hours.

Pregnancy Considerations: Ampicillin is widely used during pregnancy(Former FDA category B). ACOG guidelines recommend that pregnant mothers with preterm PROM(premature rupture of membranes) should be treated with intravenous ampicillin and erythromycin, followed by oral antibiotics to decrease neonatal complications.[15] In addition, listeriosis during pregnancy has been associated with vertical transmission in newborns and higher mortality, for which ampicillin is often used with other antibiotics.[16] 

Breastfeeding Considerations: Clinical data suggest that administration of ampicillin during lactation produces low levels in milk that are not anticipated to cause adverse effects in breastfed infants. However, alteration of the infant's gastrointestinal flora has been reported; consequently, when ampicillin is used during lactation, monitor for diarrhea and thrush.[17]

Adverse Effects

Serious Adverse Drug Reactions

  • The primary adverse effects of ampicillin include seizure, enterocolitis, agranulocytosis, hemolytic anemia, immune thrombocytopenia, and pseudomembranous colitis.[18]

Local Adverse Reactions

  • Pain at IM/IV injection site 
  • Thrombophlebitis 

Hypersensitivity Reactions

  • Rashes and urticaria occur frequently.
  • Reports also exist of some cases of erythema multiforme and exfoliative dermatitis.
  • Anaphylaxis is the most severe complication experienced and is usually associated with the parenteral form. Anaphylaxis is life-threatening and requires rapid treatment.[19][20]

Gastrointestinal Adverse Drug Reactions

  • Stomatitis
  • Pseudomembranous colitis
  • Enterocolitis
  • Black hairy tongue
  • Mainly seen with oral dose administration).[21]


  • A moderate elevation of serum glutamic oxaloacetic transaminase (SGOT/AST) is reported, commonly in infants; its significance is unknown. Mild transient elevations are possible with repeated intramuscular administration in individuals receiving larger than usual doses. Evidence indicates that AST gets released in the intramuscular injection site, and the increased quantities seen in the blood may not necessarily be from the liver as a source.
  • Isolated instances of idiosyncratic liver injury have been reported in persons receiving ampicillin. The serum enzyme pattern is a hepatocellular pattern with marked elevations in ALT and AST, minimal elevations in alkaline phosphatase, and rapid recovery after withdrawal.
  • In addition, cholestatic forms of hepatic injury with marked alkaline phosphatase elevations have also been infrequently described with vanishing bile duct syndrome.[22]


  • Case reports of ampicillin-sulbactam-induced nephrotoxicity and AKI have been reported, mainly when used in combination with vancomycin.[23]

Neurological Adverse Drug Reactions

  • Headache

Hematological Adverse Drug Reactions

  • Reports exist of anemia, thrombocytopenic purpura, thrombocytopenia, eosinophilia, agranulocytosis, and leukopenia during ampicillin therapy.
  • These reactions are reversible on discontinuation of therapy, the etiology being a hypersensitive phenomenon.[25]

Opportunistic Infections

  • During therapy, superinfection with some bacteria or mycotic organisms is possible.
  • Opportunistic infection warrants discontinuation of therapy and substitution of appropriate treatment.[26][27]

Drug-Drug Interactions

  • Stevens-Johnson syndrome (SJS) has been reported due to the concomitant use of ampicillin and allopurinol.[28]


Infection by penicillinase-producing organisms

  • Ampicillin is contraindicated in the treatment of infections caused by penicillinase-producing organisms. The rationale behind it is penicillinase (beta-lactamase) will inactivate ampicillin.


  • Severe and life-threatening anaphylactoid reactions can occur with penicillin therapy. Although anaphylaxis more commonly occurs following parenteral therapy, it can also present after oral administration. It is more likely in patients with a previous history of penicillin hypersensitivity and reaction to multiple allergens. Before initiating therapy, the clinician should carefully inquire about hypersensitivity reactions to cephalosporins, allergens, or penicillin.
  • If a hypersensitivity reaction occurs, the clinician should discontinue ampicillin therapy and initiate alternative antimicrobial therapy. Anaphylactoid reactions require immediate emergency treatment with oxygen, epinephrine, steroids, and airway management, including intubation(if clinically indicated).[19]

Clostridium Difficile Infection 

  • Antibacterial treatment alters the intestine's natural flora, leading to the overgrowth of C. difficile. Clostridioides difficile-associated diarrhea (CDAD) can occur with nearly all antibacterial agents, especially ampicillin. The resulting severity may range from mild diarrhea to fulminant colitis. Hypertoxin-producing C. difficile strains cause increased morbidity and mortality, as these strains are refractory to the recommended antimicrobial therapy and may require colectomy. Therefore, CDAD is a consideration for all patients who present with diarrhea after antibacterial use. Since it is reported to occur over two months after administering antibacterial agents, a careful medical history is necessary in these cases.
  • If CDAD is confirmed, ongoing antimicrobial use not directed against the organism might require cessation of therapy. Adequate fluid and electrolyte management, protein supplementation, and the antimicrobial regimen of C. difficile and surgical evaluation should be an option if indicated.[26]

Concomitant Infectious Mononucleosis Infection

  • A high proportion (43%) of patients with infectious mononucleosis started on ampicillin can develop a rash. Ideally, the rash appears 7 to 10 days following the initiation of ampicillin therapy and remains for a few days to one week after discontinuation of the drug. In most cases, the rash is maculopapular, generalized, and pruritic. Therefore, ampicillin administration is not a recommendation for these patients. Whether these patients are truly allergic to penicillin remains unknown.[29]

Absence of Strong Indication

  • Ampicillin administration without a specific indication or proof of a bacterial infection or a prophylactic indication is not likely to benefit the patient. Instead, it increases the risk of the growth of drug-resistant bacteria.[30]


  • When prescribing ampicillin for a long duration, monitor renal and hepatic function. 
  • Additionally, monitor for signs and symptoms of anaphylaxis during the first dose.[31]
  • Providers should carefully monitor the parenteral solution for particulate matter and discoloration and discard it if needed.[32]


  • Neurological adverse reactions, including convulsions, may occur due to high CSF concentrations of ampicillin.
  • Management of overdose requires medication discontinuation, symptomatic treatment, and supportive care.
  • Previously, whole bowel irrigation has been reported to be effective in severe cases of oral overdoses.[33]
  • In patients with decreased renal function, ampicillin is removable via hemodialysis but not peritoneal dialysis.[34]
  • In case of anaphylaxis, epinephrine should be administered without delay. According to AAFP, after administering epinephrine, clinicians should administer adjunctive treatment, including corticosteroids, antihistamines, and beta2 agonists. Referral to an allergist/immunologist should be considered.[35]

Enhancing Healthcare Team Outcomes

Ampicillin is a widely prescribed antimicrobial by clinicians and other healthcare professionals working collaboratively as an interprofessional team. While the antimicrobial is effective, clinicians should not empirically prescribe for all infections as the resistance to this agent is increasing globally. Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials. According to CDC, core elements of outpatient antimicrobial stewardship are commitment, action for policy and practice, tracking and reporting, education, and expertise.[36]

Nephrology consultation is essential for hemodialysis. Pharmacists should verify dosing, look into the appropriateness of selecting ampicillin-sulbactam based on the infection type and available antibiogram data, and check for drug-drug interactions. In most cases, nurses administer this drug, monitor for adverse events, and assess therapeutic effectiveness, informing the clinician of their findings as treatment progresses. In the case of an overdose, emergency department physicians and nurses should rapidly stabilize the patient. 

As outlined above, various healthcare providers, including clinicians (MDs, DOs, NPs, PAs), specialists, nurses, and pharmacists, participate in an interprofessional team-based approach to optimize patient care. Additionally, antimicrobial stewardship is necessary for reducing global drug resistance. An observational study of eight years involving twenty-three antibiotics, including ampicillin, demonstrated that rates of Clostridioides difficile infection (CDI) could be reduced using interprofessional antimicrobial stewardship between clinicians, pharmacists, infection control nurses, and other healthcare professionals.[37] [Level 3]



Kaushik D, Mohan M, Borade DM, Swami OC. Ampicillin: rise fall and resurgence. Journal of clinical and diagnostic research : JCDR. 2014 May:8(5):ME01-3. doi: 10.7860/JCDR/2014/8777.4356. Epub 2014 May 15     [PubMed PMID: 24995206]


Biggs BA, Kucers A. Penicillins and related drugs. The Medical journal of Australia. 1986 Dec 1-15:145(11-12):607-11     [PubMed PMID: 3540540]


Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, Bisno AL, Ferrieri P, Shulman ST, Durack DT. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA. 1995 Dec 6:274(21):1706-13     [PubMed PMID: 7474277]

Level 1 (high-level) evidence


Heintz BH, Halilovic J, Christensen CL. Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy. 2010 Nov:30(11):1136-49. doi: 10.1592/phco.30.11.1136. Epub     [PubMed PMID: 20973687]

Level 3 (low-level) evidence


Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant Salmonella typhi: a worldwide epidemic. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1997 Jan:24 Suppl 1():S106-9     [PubMed PMID: 8994789]


Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA, American Society of Health-System Pharmacists, Infectious Disease Society of America, Surgical Infection Society, Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013 Feb 1:70(3):195-283. doi: 10.2146/ajhp120568. Epub     [PubMed PMID: 23327981]

Level 1 (high-level) evidence


Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR, Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013 Jan:56(1):e1-e25. doi: 10.1093/cid/cis803. Epub 2012 Dec 6     [PubMed PMID: 23223583]

Level 1 (high-level) evidence


Conde-Agudelo A, Romero R, Jung EJ, Garcia Sánchez ÁJ. Management of clinical chorioamnionitis: an evidence-based approach. American journal of obstetrics and gynecology. 2020 Dec:223(6):848-869. doi: 10.1016/j.ajog.2020.09.044. Epub 2020 Sep 29     [PubMed PMID: 33007269]


Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2022 Aug 25:75(2):187-212. doi: 10.1093/cid/ciac268. Epub     [PubMed PMID: 35439291]


Tipper DJ. Mode of action of beta-lactam antibiotics. Pharmacology & therapeutics. 1985:27(1):1-35     [PubMed PMID: 3889939]


Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrobial agents and chemotherapy. 2015 Mar:59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5     [PubMed PMID: 25561334]


Sullins AK,Abdel-Rahman SM, Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatric drugs. 2013 Apr     [PubMed PMID: 23529866]


Padari H,Soeorg H,Tasa T,Metsvaht T,Kipper K,Herodes K,Oselin K,Hallik M,Ilmoja ML,Lutsar I, Ampicillin Pharmacokinetics During First Week of Life in Preterm and Term Neonates. The Pediatric infectious disease journal. 2021 May 1;     [PubMed PMID: 33591074]


Temple ME, Nahata MC. Treatment of listeriosis. The Annals of pharmacotherapy. 2000 May:34(5):656-61     [PubMed PMID: 10852095]


Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery. Obstetrics and gynecology. 2018 Sep:132(3):e103-e119. doi: 10.1097/AOG.0000000000002833. Epub     [PubMed PMID: 30134425]


Wang Z, Tao X, Liu S, Zhao Y, Yang X. An Update Review on Listeria Infection in Pregnancy. Infection and drug resistance. 2021:14():1967-1978. doi: 10.2147/IDR.S313675. Epub 2021 May 26     [PubMed PMID: 34079306]


. Ampicillin. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 30000053]


Dicks LMT, Mikkelsen LS, Brandsborg E, Marcotte H. Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics. Current microbiology. 2019 Jun:76(6):774-782. doi: 10.1007/s00284-018-1543-8. Epub 2018 Aug 6     [PubMed PMID: 30084095]


Mirakian R,Leech SC,Krishna MT,Richter AG,Huber PA,Farooque S,Khan N,Pirmohamed M,Clark AT,Nasser SM, Management of allergy to penicillins and other beta-lactams. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2015 Feb;     [PubMed PMID: 25623506]


Soar J, Pumphrey R, Cant A, Clarke S, Corbett A, Dawson P, Ewan P, Foëx B, Gabbott D, Griffiths M, Hall J, Harper N, Jewkes F, Maconochie I, Mitchell S, Nasser S, Nolan J, Rylance G, Sheikh A, Unsworth DJ, Warrell D, Working Group of the Resuscitation Council (UK). Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Resuscitation. 2008 May:77(2):157-69. doi: 10.1016/j.resuscitation.2008.02.001. Epub 2008 Mar 20     [PubMed PMID: 18358585]


Gurvits GE,Tan A, Black hairy tongue syndrome. World journal of gastroenterology. 2014 Aug 21;     [PubMed PMID: 25152586]


. Ampicillin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31643230]


Rutter WC,Burgess DS, Acute Kidney Injury in Patients Treated with IV Beta-Lactam/Beta-Lactamase Inhibitor Combinations. Pharmacotherapy. 2017 May     [PubMed PMID: 28247443]


Hornik CP, Benjamin DK Jr, Smith PB, Pencina MJ, Tremoulet AH, Capparelli EV, Ericson JE, Clark RH, Cohen-Wolkowiez M, Best Pharmaceuticals for Children Act—Pediatric Trials Network. Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. The Journal of pediatrics. 2016 Nov:178():125-129.e1. doi: 10.1016/j.jpeds.2016.07.011. Epub 2016 Aug 10     [PubMed PMID: 27522443]


Massoll AF, Powers SC, Betten DP. Agranulocytosis occurrence following recent acute infectious mononucleosis. The American journal of emergency medicine. 2017 May:35(5):803.e5-803.e6. doi: 10.1016/j.ajem.2016.11.042. Epub 2016 Nov 19     [PubMed PMID: 27912922]


Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet (London, England). 1990 Jul 14:336(8707):97-100     [PubMed PMID: 1975332]


Oldfield EC 3rd. Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment. Reviews in gastroenterological disorders. 2004 Fall:4(4):186-95     [PubMed PMID: 15580153]


Cheng FJ, Syu FK, Lee KH, Chen FC, Wu CH, Chen CC. Correlation between drug-drug interaction-induced Stevens-Johnson syndrome and related deaths in Taiwan. Journal of food and drug analysis. 2016 Apr:24(2):427-432. doi: 10.1016/j.jfda.2015.11.009. Epub 2016 Jan 14     [PubMed PMID: 28911598]


Thompson DF,Ramos CL, Antibiotic-Induced Rash in Patients With Infectious Mononucleosis. The Annals of pharmacotherapy. 2017 Feb;     [PubMed PMID: 27620494]


Heinz E, The return of Pfeiffer's bacillus: Rising incidence of ampicillin resistance in Haemophilus influenzae. Microbial genomics. 2018 Sep     [PubMed PMID: 30207515]


Kuruvilla M, Khan DA. Anaphylaxis to drugs. Immunology and allergy clinics of North America. 2015 May:35(2):303-19. doi: 10.1016/j.iac.2015.01.008. Epub 2015 Mar 3     [PubMed PMID: 25841553]


Allen LV Jr. Sterile Basics of Compounding: Particulates in Parenteral Preparations: Sources, Minimization, and Detection. International journal of pharmaceutical compounding. 2022 May-Jun:26(3):219-228     [PubMed PMID: 35657746]


Tenenbein M,Cohen S,Sitar DS, Whole bowel irrigation as a decontamination procedure after acute drug overdose. Archives of internal medicine. 1987 May;     [PubMed PMID: 3579442]


King JD, Kern MH, Jaar BG. Extracorporeal Removal of Poisons and Toxins. Clinical journal of the American Society of Nephrology : CJASN. 2019 Sep 6:14(9):1408-1415. doi: 10.2215/CJN.02560319. Epub 2019 Aug 22     [PubMed PMID: 31439539]


Wang T, Ma X, Xing Y, Sun S, Zhang H, Stürmer T, Wang B, Li X, Tang H, Jiao L, Zhai S. Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database. International archives of allergy and immunology. 2017:173(1):51-60. doi: 10.1159/000475498. Epub 2017 May 16     [PubMed PMID: 28505618]


Sanchez GV,Fleming-Dutra KE,Roberts RM,Hicks LA, Core Elements of Outpatient Antibiotic Stewardship. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2016 Nov 11     [PubMed PMID: 27832047]


Yoshida J, Kikuchi T, Ueno T, Mataga A, Asano I, Otani K, Tamura T, Tanaka M. Interprofessional Antimicrobial Stewardship Influencing Clostridioides difficile Infection: An 8-Year Study Using Antimicrobial Use Density. Infection and drug resistance. 2019:12():3409-3414. doi: 10.2147/IDR.S184050. Epub 2019 Nov 4     [PubMed PMID: 31807031]